Aktiesnakken — November 2009
-
De er netop ved at sætte mere fokus på den ullovlige marekdsførring af offlabel indikationer. Myndighederne vil have det stoppet
-
Og de har lige givet pfizer en bøde på $2 mia for netop at marekdsføre offlabel indikationer
-
men når man så samtidig giver reimbursment til offlabel....... spørgsmålet er så om den praksis får lov at fortsætte
-
hvad var fase 3 resultaterne for ritux?? i cll 1st line
-
her er nogle rituximab fase 3 data http://journals.lww.com/oncology-times/Fulltext/2009/02101/CLL__Phase_III_Studies_Confirm_Added_Rituximab.4.aspx
-
det kan være bivirkningerne og det er GREAT news for Arzerra
-
hese gains, though, were bought at the price of increased toxicity, with severe hematologic toxicity up from 39% to 55% of patients in the i
-
ok ser faktisk de var lunkne allerede dengang
-
he glaring fact is that rituximab by itself, at conventional doses, is very inactive in CLL
-
The glaring fact is that rituximab by itself, at conventional doses, is very inactive in CLL
-
måske beater Arzerra Ritux bigtime i CLL
-
for fanden da vi vidste da ikke noget om at de ikke var blevet godkendt
-
er ritux overhovedet godkendt i CLL??
-
know your competitor
-
men i følge artiklen er det kun nhl og ra det er godkendt i. Det er dog også de 2 største indikationer
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind